CAS NO: | 355827-05-3 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
Cas No. | 355827-05-3 |
化学名 | 2-[[(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]-benzonitrile |
Canonical SMILES | BrC1=CNC2=NC(SCC3=CC=CC=C3C#N)=NC2=C1 |
分子式 | C14H9BrN4S |
分子量 | 345.2 |
溶解度 | ≤12mg/ml in DMSO;14mg/ml in dimethyl formamide |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Target: NAD+-dependent type-I 15-hydroxy PGDH IC50: 26.4 nM Ki: 5 nM STK393606 is a competitive inhibitor of NAD+-dependent type-I 15-hydroxy PGDH, with the IC50 value of 26.4±2.4 nM, and the Ki value of 5 nM, which could cause a maximum of 100% inhibition [1]. Hydroxyprostaglandin dehydrogenase 15-(NAD), also called 15-hydroxy prostaglandin dehydrogenase (15-hydroxy PGDH), is a critical enzyme participated in the inactivation of prostaglandins (PGs) and related eiscosanoids. 15-hydroxy PGDH belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of substrates with NAD+ or NADP+ as acceptor. 15-hydroxy PGDH could catalyze the oxidation of primary PGs to their 15-keto metabolites [2]. Radioimmunoassay for 15-hydroxy prostaglandin dehydrogenase had identified two types of enzyme activity, of which type-I used NAD+ as a cofactor, while type-II used NADP+ as a cofactor and bear wider substrate specificity [3]. In Vitro: no data available. In Vivo: no data available. Clinical trial: no data available. References: |